Hennion & Walsh Asset Management, Inc.
Position in LXRX — Lexicon Pharmaceuticals, Inc.
CIK 1861642
Parsippany, NJ
Position in LXRX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,323,095
+$286,690 QoQ
Shares Held
848,138
-5.9% QoQ
Ownership
0.191%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $200,308,891 across 60 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
48,019 | $11,571,138 | |
| 2 | CELC |
Celcuity Inc.
|
100,368 | $10,500,500 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
276,696 | $10,182,412 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
171,470 | $9,741,210 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
342,883 | $7,495,422 | |
| 6 | QURE |
uniQure N.V.
|
142,113 | $6,545,724 | |
| 7 | KURA |
Kura Oncology, Inc.
|
568,845 | $6,240,229 | |
| 8 | ARDX |
Ardelyx, Inc.
|
1,211,690 | $6,179,619 |
All Filings in LXRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,323,095 | 848,138 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,036,405 | 901,222 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $1,051,936 | 779,212 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $753,730 | 793,400 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $381,824 | 830,054 | Shares | Sole | 2025-04-10 | |
| 2024-12-31 | $638,808 | 863,255 | Shares | Sole | 2025-01-15 | |
| 2024-09-30 | $1,147,886 | 731,138 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $912,070 | 542,899 | Shares | Sole | 2024-07-19 | |
| No filing history on record for this holder in this stock. | ||||||